RxSight, Inc.: updates and filings

RXSTNASDAQHealthcare · Ophthalmic Goods

Price

$5.01

November 18, 2026Market cap $207M

What Ploutos Investor adds for RxSight

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 77 daysAround Feb 4, 2027 · for Q4 2026

last Nov 3, 2026next Feb 4, 2027

A rough estimate from when it has reported before, which has varied. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 25, 2026 latest annualNov 3, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 10, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 3, 2026Shares registered for employees
    FormS-8
  • Nov 3, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 3, 2026Results of operations
    Form8-K
  • Nov 2, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 27, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 27, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Sep 8, 2026Filing (amendment)
    FormSC TO-I/A
  • Aug 25, 2026Filing (amendment)
    FormSC TO-I/A
  • Aug 19, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 10, 2026Filing
    FormSC TO-I
  • Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 5, 2026Results of operations
    Form8-K
  • Aug 4, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jul 23, 2026Shares registered for employees
    FormS-8
  • Jul 17, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jul 15, 2026Officer or director change, Regulation FD disclosure
    Form8-K
  • Jul 6, 2026Material agreement entered, Regulation FD disclosure
    Form8-K
  • Jul 6, 2026Results of operations
    Form8-K
  • Jun 16, 2026Shareholder vote
    Form8-K
  • May 29, 2026Conflict minerals report
    FormSD
  • May 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 6, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 6, 2026Results of operations
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 30, 2002.

The full analysis

What do RxSight's filings show?

The filings are where every one of RxSight's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.